A randomised, double‐blinded trial to assess the effect of oclacitinib and prednisolone on intradermal allergen and prick tests in dogs with atopic dermatitis
Veterinary Dermatology · 2024
DOI: 10.1111/vde.13209 ↗Kurz gefasst
Fachartikel in der Zeitschrift Veterinary Dermatology, 2024. Verfasst von Letícia Talita Baretta und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculdade de Veterinária, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Dog Diseases, Intradermal Tests. Die Arbeit nennt 34 Literaturangaben. Gefördert von: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
Abstract (Originalsprache)
Background
Intradermal (IDT) and prick (PT) tests are used to select allergens for allergen‐specific immunotherapy in dogs with atopic dermatitis (cAD). However, the use of antipruritic drugs before performing these tests may influence the results.
Objective
To evaluate the influence of the drugs oclacitinib and prednisolone on the immediate‐phase reactions of IDT and PT. Animal s Thirty client‐owned dogs with cAD with positive reactions to at least one allergen extract on IDT or PT. Materials and Methods Dogs were randomly assigned to receive oclacitinib 0.4–0.58 mg/kg per os, every 12 h ( n = 14), or prednisolone 0.37–0.65 mg/kg p.o., every 12 h ( n = 16) for 14 days. IDT and PT were performed on Day (D)0 before treatment and on D14.
Results
At D14 there was no significant reduction in the means of the orthogonal diameters of the positive immediate‐phase reactions of the IDT ( p = 0.064) in the oclacitinib group; however, in the PT, the diameter of the positive reactions reduced significantly ( p = 0.048). In both tests, there was no significant reduction in the total number of positive reactions (IDT, p > 0.999; PT, p = 0.735). In the prednisolone group, the means of the orthogonal diameters of positive immediate‐phase reactions were significantly reduced in both tests (IDT, p = 0.001; PT, p ≤ 0.001) and there also was a reduction in the total number of positive reactions (IDT, p = 0.022; PT, p = 0.001). Conclusions and Clinical Relevance The use of oclacitinib 0.4–0.58 mg/kg twice daily for 14 days does not interfere with IDT results in dogs with cAD. However, oclacitinib may reduce PT reactivity. The use of prednisolone 0.37–0.65 mg/kg twice daily results in a reduction in both IDT and PT results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculdade de Veterinária, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
- Veterinary Allergy Clinic, Rio de Janeiro, Brazil.
ORCID-Profile: Daniel Guimarães Gerardi
Förderung
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Zitieren
APA
Baretta, L. T., do Espírito Santo Cunha, V., Figueiredo, C. D., & Gerardi, D. G. (2024). A randomised, double‐blinded trial to assess the effect of oclacitinib and prednisolone on intradermal allergen and prick tests in dogs with atopic dermatitis. Veterinary Dermatology. https://doi.org/10.1111/vde.13209
Vancouver
Baretta LT, do Espírito Santo Cunha V, Figueiredo CD, Gerardi DG. A randomised, double‐blinded trial to assess the effect of oclacitinib and prednisolone on intradermal allergen and prick tests in dogs with atopic dermatitis. Veterinary Dermatology. 2024. doi:10.1111/vde.13209
BibTeX
@article{Baretta2024,
author = {Baretta, Letícia Talita and do Espírito Santo Cunha, Victor and Figueiredo, Cristiane Deon and Gerardi, Daniel Guimarães},
title = {A randomised, double‐blinded trial to assess the effect of oclacitinib and prednisolone on intradermal allergen and prick tests in dogs with atopic dermatitis},
journal = {Veterinary Dermatology},
year = {2024},
doi = {10.1111/vde.13209}
}
EUVIMED